T80.818D Extravasation of other vesicant agent, subsequent encounterBillable ICD-10-CM code, FY2026.
Built from T80.818 with 7th character D (subsequent encounter).
T80.1 Vascular complications following infusion, transfusion and therapeutic injection ("extravasation of vesicant agent (T80.81-)")T80.1 Vascular complications following infusion, transfusion and therapeutic injection ("infiltration of vesicant agent (T80.81-)")T45.8 Poisoning by, adverse effect of and underdosing of other primarily systemic and hematological agents ("transfusion reactions (T80.-)")T78 Adverse effects, not elsewhere classified ("complications of surgical and medical care NEC (T80-T88)")T79 Certain early complications of trauma, not elsewhere classified ("complications occurring during or following medical procedures (T80-T88)")T79 Certain early complications of trauma, not elsewhere classified ("complications of surgical and medical care NEC (T80-T88)")T81 Complications of procedures, not elsewhere classified ("complications following infusion, transfusion and therapeutic injection (T80.-)")T88 Other complications of surgical and medical care, not elsewhere classified ("complication following infusion, transfusion and therapeutic injection (T80.-)")T88.7 Unspecified adverse effect of drug or medicament ("specified adverse effects of drugs and medicaments (A00-R94 and T80-T88.6, T88.8)")T80.810A Extravasation of vesicant antineoplastic chemotherapy, initial encounterT80.810D Extravasation of vesicant antineoplastic chemotherapy, subsequent encounterT80.810S Extravasation of vesicant antineoplastic chemotherapy, sequelaT80.818 Extravasation of other vesicant agentT80.818A Extravasation of other vesicant agent, initial encounterT80.818D Extravasation of other vesicant agent, subsequent encounter (this code)T80.818S Extravasation of other vesicant agent, sequelaT80.82 Complication of immune effector cellular therapyT80.82XA Complication of immune effector cellular therapy, initial encounterT80.82XD Complication of immune effector cellular therapy, subsequent encounterT80.82XS Complication of immune effector cellular therapy, sequela